Related references
Note: Only part of the references are listed.Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014
Steinbjorn Hansen et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
Bengt Glimelius et al.
ACTA ONCOLOGICA (2018)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden
Maria Sandstrom et al.
ANTICANCER RESEARCH (2017)
Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009
Dorothee Gramatzki et al.
CANCER (2016)
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan et al.
CANCER RESEARCH (2016)
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio
Olivier L. Chinot et al.
NEURO-ONCOLOGY (2016)
Brain tumors in Sweden: Data from a population-based registry 1999-2012
Thomas Asklund et al.
ACTA ONCOLOGICA (2015)
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors
Hiroto Kawano et al.
BRITISH JOURNAL OF NEUROSURGERY (2015)
The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme
Lola B. Chambless et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients
Jennifer E. Adair et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
Kaisorn L. Chaichana et al.
NEURO-ONCOLOGY (2014)
Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study
Giuseppe Stragliotto et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Impact of extent of resection for recurrent glioblastoma on overall survival Clinical article
Orin Bloch et al.
JOURNAL OF NEUROSURGERY (2012)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis A review
Abraham Tsitlakidis et al.
JOURNAL OF NEUROSURGERY (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The Rescue Approach
James R. Perry et al.
CANCER (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Glioma extent of resection and its impact on patient outcome
Nader Sanai et al.
NEUROSURGERY (2008)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
W Stummer et al.
LANCET ONCOLOGY (2006)
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
G Dresemann
ANNALS OF ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
ER Laws et al.
JOURNAL OF NEUROSURGERY (2003)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma:: A phase II study
AA Brandes et al.
ANNALS OF ONCOLOGY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
